Kaufmann Christopher N, Spira Adam P, Alexander G Caleb, Rutkow Lainie, Mojtabai Ramin
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):637-45. doi: 10.1002/pds.3951. Epub 2015 Dec 29.
Non-benzodiazepine receptor agonists (nBZRAs) were developed as an alternative to benzodiazepines (BZDs) to treat insomnia. Little is known about how the introduction of nBZRAs influenced trends in BZD prescribing. We examined BZD and nBZRA prescribing trends from 1993 to 2010.
We used the National Ambulatory Medical Care Survey to examine 516,118 patient visits between 1993 and 2010. We categorized visits as BZD, nBZRA, or BZD + nBZRA visits based on medications prescribed in each visit and applied linear probability regression models to assess trends in visits.
Increases were observed in proportions of visits that were BZD (2.6% in 1993 to 4.4% in 2010, p < 0.001) and nBZRA (0% to 1.4%, p < 0.001). Increases in BZD visits were primarily after 2002, with prescribing in the preceding years remaining relatively stable. We also found increases in BZD + nBZRA visits (0% to 0.4%, p < 0.001). Among patients with sleep disorders, there was an increase in nBZRA visits (2.3% to 13.7%, p < 0.001), and decline in BZD visits (23.5% to 10.8%, p = 0.015). Just under a third (30.8%) of any sedative-hypnotic visits were for adults aged 65+ years, among whom increases in BZD, nBZRA, and BZD + nBZRA visits were observed across the study period.
There were increases in prescribing of nBZRAs between 1993 and 2010. Increases in prescribing of BZDs were also observed, especially after 2002. The introduction of nBZRAs likely resulted in declines in BZD prescribing among those with a sleep disorder, but not other groups. Delivery of behavioral treatments should be encouraged to avert adverse outcomes associated with sedative-hypnotic use. Copyright © 2015 John Wiley & Sons, Ltd.
非苯二氮䓬受体激动剂(nBZRAs)作为苯二氮䓬类药物(BZDs)的替代品被开发用于治疗失眠。关于nBZRAs的引入如何影响BZDs处方趋势,人们了解甚少。我们研究了1993年至2010年期间BZDs和nBZRAs的处方趋势。
我们使用国家门诊医疗调查来研究1993年至2010年间的516,118次患者就诊情况。根据每次就诊所开药物,我们将就诊分为BZD、nBZRA或BZD + nBZRA就诊,并应用线性概率回归模型来评估就诊趋势。
BZD就诊比例有所增加(从1993年的2.6%增至2010年的4.4%,p < 0.001),nBZRA就诊比例也增加(从0%增至1.4%,p < 0.001)。BZD就诊增加主要发生在2002年之后,前几年的处方量相对稳定。我们还发现BZD + nBZRA就诊也有所增加(从0%增至0.4%,p < 0.001)。在睡眠障碍患者中,nBZRA就诊增加(从2.3%增至13.7%,p < 0.001),BZD就诊减少(从23.5%降至10.8%,p = 0.015)。在所有镇静催眠药物就诊中,近三分之一(30.8%)是针对65岁及以上成年人的,在整个研究期间,该年龄段的BZD、nBZRA和BZD + nBZRA就诊均有所增加。
1993年至2010年间,nBZRAs的处方量有所增加。BZDs的处方量也有所增加,尤其是在2002年之后。nBZRAs的引入可能导致睡眠障碍患者中BZDs处方量下降,但其他群体并非如此。应鼓励提供行为治疗以避免与使用镇静催眠药物相关的不良后果。版权所有© 2015约翰威立父子有限公司。